Ethnic inequalities in positive SARS-CoV-2 tests, infection prognosis, COVID-19 hospitalisations and deaths: analysis of 2 years of a record linked national cohort study in Scotland.


Journal

Journal of epidemiology and community health
ISSN: 1470-2738
Titre abrégé: J Epidemiol Community Health
Pays: England
ID NLM: 7909766

Informations de publication

Date de publication:
10 2023
Historique:
received: 28 02 2023
accepted: 17 07 2023
medline: 11 9 2023
pubmed: 1 8 2023
entrez: 31 7 2023
Statut: ppublish

Résumé

This study aims to estimate ethnic inequalities in risk for positive SARS-CoV-2 tests, COVID-19 hospitalisations and deaths over time in Scotland. We conducted a population-based cohort study where the 2011 Scottish Census was linked to health records. We included all individuals ≥ 16 years living in Scotland on 1 March 2020. The study period was from 1 March 2020 to 17 April 2022. Self-reported ethnic group was taken from the census and Cox proportional hazard models estimated HRs for positive SARS-CoV-2 tests, hospitalisations and deaths, adjusted for age, sex and health board. We also conducted separate analyses for each of the four waves of COVID-19 to assess changes in risk over time. Of the 4 358 339 individuals analysed, 1 093 234 positive SARS-CoV-2 tests, 37 437 hospitalisations and 14 158 deaths occurred. The risk of COVID-19 hospitalisation or death among ethnic minority groups was often higher for White Gypsy/Traveller (HR 2.21, 95% CI (1.61 to 3.06)) and Pakistani 2.09 (1.90 to 2.29) groups compared with the white Scottish group. The risk of COVID-19 hospitalisation or death following confirmed positive SARS-CoV-2 test was particularly higher for White Gypsy/Traveller 2.55 (1.81-3.58), Pakistani 1.75 (1.59-1.73) and African 1.61 (1.28-2.03) individuals relative to white Scottish individuals. However, the risk of COVID-19-related death following hospitalisation did not differ. The risk of COVID-19 outcomes for ethnic minority groups was higher in the first three waves compared with the fourth wave. Most ethnic minority groups were at increased risk of adverse COVID-19 outcomes in Scotland, especially White Gypsy/Traveller and Pakistani groups. Ethnic inequalities persisted following community infection but not following hospitalisation, suggesting differences in hospital treatment did not substantially contribute to ethnic inequalities.

Sections du résumé

BACKGROUND
This study aims to estimate ethnic inequalities in risk for positive SARS-CoV-2 tests, COVID-19 hospitalisations and deaths over time in Scotland.
METHODS
We conducted a population-based cohort study where the 2011 Scottish Census was linked to health records. We included all individuals ≥ 16 years living in Scotland on 1 March 2020. The study period was from 1 March 2020 to 17 April 2022. Self-reported ethnic group was taken from the census and Cox proportional hazard models estimated HRs for positive SARS-CoV-2 tests, hospitalisations and deaths, adjusted for age, sex and health board. We also conducted separate analyses for each of the four waves of COVID-19 to assess changes in risk over time.
FINDINGS
Of the 4 358 339 individuals analysed, 1 093 234 positive SARS-CoV-2 tests, 37 437 hospitalisations and 14 158 deaths occurred. The risk of COVID-19 hospitalisation or death among ethnic minority groups was often higher for White Gypsy/Traveller (HR 2.21, 95% CI (1.61 to 3.06)) and Pakistani 2.09 (1.90 to 2.29) groups compared with the white Scottish group. The risk of COVID-19 hospitalisation or death following confirmed positive SARS-CoV-2 test was particularly higher for White Gypsy/Traveller 2.55 (1.81-3.58), Pakistani 1.75 (1.59-1.73) and African 1.61 (1.28-2.03) individuals relative to white Scottish individuals. However, the risk of COVID-19-related death following hospitalisation did not differ. The risk of COVID-19 outcomes for ethnic minority groups was higher in the first three waves compared with the fourth wave.
INTERPRETATION
Most ethnic minority groups were at increased risk of adverse COVID-19 outcomes in Scotland, especially White Gypsy/Traveller and Pakistani groups. Ethnic inequalities persisted following community infection but not following hospitalisation, suggesting differences in hospital treatment did not substantially contribute to ethnic inequalities.

Identifiants

pubmed: 37524538
pii: jech-2023-220501
doi: 10.1136/jech-2023-220501
pmc: PMC10511958
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

641-648

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 205412/Z/16/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00022/2
Pays : United Kingdom
Organisme : Chief Scientist Office
ID : SPHSU17
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: SVK was cochair of the Scottish Government’s Expert Reference Group on Ethnicity and COVID-19 and a member of the Scientific Advisory Group on Emergencies subgroup on ethnicity.

Références

EClinicalMedicine. 2020 Dec 25;31:100686
pubmed: 33409481
Trop Med Int Health. 2022 Jun;27(6):564-573
pubmed: 35411997
BMJ. 2023 Feb 23;380:448
pubmed: 36822639
BMJ. 2021 Jun 7;373:n1454
pubmed: 34099462
Lancet. 2020 May 30;395(10238):1673-1676
pubmed: 32401716
Nat Commun. 2021 Feb 10;12(1):905
pubmed: 33568663
J R Soc Med. 2021 Apr;114(4):182-211
pubmed: 33759630
Eur J Epidemiol. 2022 Dec;37(12):1215-1224
pubmed: 36333542
J Epidemiol Community Health. 2021 Oct;75(10):970-974
pubmed: 33883198
BMJ Open. 2020 Jun 21;10(6):e039097
pubmed: 32565483
BMJ Open. 2021 Aug 10;11(8):e048852
pubmed: 34376451
Lancet. 2021 May 8;397(10286):1711-1724
pubmed: 33939953
J Epidemiol Community Health. 2022 Nov 8;:
pubmed: 36347597
BMJ Open. 2020 Dec 10;10(12):e041750
pubmed: 33303461
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Clin Infect Dis. 2021 Dec 6;73(11):e4047-e4057
pubmed: 32766823
Wellcome Open Res. 2020 May 6;5:88
pubmed: 32613083
Heart. 2020 Oct;106(19):1503-1511
pubmed: 32737124
EClinicalMedicine. 2023 Mar;57:101877
pubmed: 36969795
BMC Med. 2020 May 29;18(1):160
pubmed: 32466757
J R Coll Physicians Edinb. 2021 Jun;51(S1):S40-S46
pubmed: 34185037
Front Public Health. 2022 Aug 26;10:873596
pubmed: 36091533
Int J Environ Res Public Health. 2021 Jun 18;18(12):
pubmed: 34207130
BMJ Glob Health. 2021 Nov;6(11):
pubmed: 34740916
J Glob Health. 2021 Dec 25;11:01010
pubmed: 35047182

Auteurs

Sarah Amele (S)

MRC/CSO Social and Public Health Science Unit, School of Health and Wellbeing, University of Glasgow, Glasgow, UK.

Eliud Kibuchi (E)

MRC/CSO Social and Public Health Science Unit, School of Health and Wellbeing, University of Glasgow, Glasgow, UK Eliud.Kibuchi@glasgow.ac.uk.

Ronan McCabe (R)

MRC/CSO Social and Public Health Science Unit, School of Health and Wellbeing, University of Glasgow, Glasgow, UK.

Anna Pearce (A)

MRC/CSO Social and Public Health Science Unit, School of Health and Wellbeing, University of Glasgow, Glasgow, UK.

Paul Henery (P)

Public Health Scotland, Glasgow Office, Glasgow, UK.

Kirsten Hainey (K)

MRC/CSO Social and Public Health Science Unit, School of Health and Wellbeing, University of Glasgow, Glasgow, UK.

Adeniyi Francis Fagbamigbe (AF)

Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.
Department of Epidemiology and Medical Statistics, Faculty of Public Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria.

Amanj Kurdi (A)

Strathclyde Institute of Pharmacy & Biomedical Sciences (SIPBS), Faculty of Science, University of Strathclyde, Glasgow, UK.
Department of Pharmacology,College of Pharmacy, Hawler Medical University, Erbil, Kurdistan, Iraq.

Colin McCowan (C)

School of Medicine, University of St Andrews, St Andrews, Fife, UK.

Colin R Simpson (CR)

Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK.
School of Health, Wellington Faculty of Health, Victoria University of Wellington, Wellington, New Zealand.

Chris Dibben (C)

Centre for Research on Environment, Society and Health, School of GeoSciences, Institute of Geography, University of Edinburgh, Edinburgh, UK.

Duncan Buchanan (D)

Research Data Scotland, Edinburgh, UK.

Evangelia Demou (E)

MRC/CSO Social and Public Health Science Unit, School of Health and Wellbeing, University of Glasgow, Glasgow, UK.

Fatima Almaghrabi (F)

Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK.

Gina Anghelescu (G)

Scottish Centre for Administrative Data Research (SCADR), University of Glasgow, Glasgow, UK.

Harry Taylor (H)

Department of Global Health and Social Medicine, King's College London, London, UK.

Holly Tibble (H)

Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK.

Igor Rudan (I)

Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK.

James Nazroo (J)

Department of Sociology, School of Social Sciences, The University of Manchester, Manchester, UK.

Laia Bécares (L)

Department of Global Health and Social Medicine, King's College London, London, UK.

Luke Daines (L)

Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK.

Patricia Irizar (P)

Department of Sociology, School of Social Sciences, The University of Manchester, Manchester, UK.

Sandra Jayacodi (S)

Patient and Public Involvement (PPI) Representative, Non affiliated, Glasgow, UK.

Serena Pattaro (S)

Scottish Centre for Administrative Data Research (SCADR), University of Glasgow, Glasgow, UK.

Aziz Sheikh (A)

Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK.

Srinivasa Vittal Katikireddi (SV)

MRC/CSO Social and Public Health Science Unit, School of Health and Wellbeing, University of Glasgow, Glasgow, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH